MétaCan
Menu
Back to cohort
Record W4417123556 · doi:10.3389/fimmu.2025.1730346

Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products

2025· article· en· W4417123556 on OpenAlexfundno aff
Aimee E. Mattei, Brian Roberts, Sandra Lélias, Shah Jahan Miah, Kristina E. Howard, James L. Weaver, Daniela Verthelyi, Eric Pang, Katie J. Edwards, Anne S. De Groot

Bibliographic record

VenueFrontiers in Immunology · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
Topicvaccines and immunoinformatics approaches
Canadian institutionsnot available
FundersU.S. Food and Drug AdministrationHamilton Health Sciences Foundation
KeywordsImmunogenicityTeriparatideDrugEpitopeRisk assessmentBioequivalenceImmune systemPeripheral blood mononuclear cell

Abstract

fetched live from OpenAlex

Teriparatide is one of several generic peptides named in a recent Food and Drug Administration (FDA) guidance (FDA-2017-D-5767-0002), which outlines a potential strategy to inform immunogenicity risk assessment for synthetic generic peptides without requiring clinical studies. Specifically, the guidance states that for abbreviated new drug applications (ANDAs), once the sameness of the active pharmaceutical ingredient (API) between the generic product and the reference listed drug is established, developers can mitigate the residual risk of unwanted immunogenicity response by using in silico and in vitro tools to characterize differences in product- and process-related impurities between the reference and generic drug products. Regarding product-related impurities, a stated concern is that sequence modifications may create new T-cell epitopes capable of driving unwanted immune responses. Specifically, the guidance sets limits for the relative abundance of each impurity and requests that any new impurity above a certain concentration threshold be evaluated for potential T-cell-driven immunogenicity using orthogonal methods that assess both human leukocyte antigen (HLA) binding and the capacity to elicit a T-cell response. One such orthogonal immunogenicity risk assessment approach was applied to teriparatide (TPT) and several theoretical or observed product-related impurities in the case study described here. First, the immunogenic potential of TPT and selected impurities was assessed using three in silico tools: EpiMatrix, ClustiMer, and JanusMatrix. Second, an in vitro method was used to evaluate the binding affinity of TPT and the selected TPT impurities to different class II HLA-DRs in vitro . Third, a human peripheral blood mononuclear cell (PBMC) T-cell assay compared T-cell proliferation in response to individual impurities or the reference teriparatide drug product, Forteo ® , in vitro . The orthogonal approaches identified multiple impurities as more immunogenic than TPT. In a novel finding, the in silico analysis revealed a potentially tolerogenic sequence in TPT, which correlated with lower-than-expected de novo immune responses to TPT in vitro . The analysis and methods described in this case study may help assess the relative risk of impurities and help identify those with the potential to increase the immunogenicity risk of a generic peptide.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.501
Threshold uncertainty score0.862

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.236
Teacher spread0.230 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueFrontiers in ImmunologySame topicvaccines and immunoinformatics approachesFrench-language works237,207